Advances in the management of congenital heart disease in children have resulted in growing numbers of adults with adult congenital heart disease (ACHD), which has recently been reviewed.
Advances in the management of congenital heart disease in children have resulted in growing numbers of adults with adult congenital heart disease (ACHD), which has recently been reviewed. 1, 2 Pulmonary hypertension (PH) related to ACHD is a common complication affecting up to 10% of patients, a disorder that can develop even after successful and complete defect repair, often with severe morbidity and even potentially fatal consequences. 3 The pathophysiology and consequences of PH may differ considerably in ACHD and non-ACHD patients.
Certainly, besides impacting survival, PH may markedly increase the symptoms of exertional dyspnea and exercise intolerance. In addition to comprehensive clinical phenotyping, clinical centers often employ cardiopulmonary stress testing (CPX) as part of a comprehensive evaluation when indicated; and CPX is presently most common in the evaluation of patients with unexplained dyspnea and heart failure (HF), while its use in suspected or confirmed PH is increasing. 4 Indeed, this form of physiological testing not only quantifies functional capacity, which is often a potent predictor of prognosis and survival, but it also provides information on the degree of circulatory impairment, ventilatory impairment, deconditioning, and the impact various combinations of these disorders have on clinical status. [4] [5] [6] [7] [8] [9] [10] Reviews demonstrating the value of CPX in the evaluation of patients with PH are available. 11, 12 A primary pathophysiological driver of the diminished exercise capacity in patients with PH is a decrease in right ventricular cardiac output secondary to elevated pulmonary artery pressure (PAP). 9, 11, 12 Downstream left ventricular cardiac output is decreased, leading to reduced skeletal muscle perfusion. The two primary parameters with expiratory gas analysis and CPX to evaluate PH is the minute ventilation/carbon dioxide production (VE/VCO 2 ) slope and peak oxygen consumption (VO 2 ). Assessing the relationship between VE and VCO 2 allows for an assessment of how well pulmonary perfusion matches pulmonary ventilation. With an increase in PAP, there is a reduction in pulmonary perfusion while pulmonary ventilation remains sufficient. The decrease in VCO 2 and normal VE results in a significant increase in the VE/VCO 2 slope in PH, well beyond the normal threshold (i.e. >30). The greater the rise in PAP and reduction in right ventricular cardiac output is reflected by a progressively higher VE/VCO 2 slope. As such, the VE/VCO 2 slope is an indicator of the severity of the primary pathophysiology in PH. Downstream, the decrease in left ventricular cardiac output and decreasing tissue perfusion is reflected by decreasing peak VO 2 . 9, 11, 12 In the present issue of the European Journal of Preventive Cardiology, Righini and colleagues 13 from four centres in Europe evaluated 167 patients with PH, including 57 with ACHD and 110 with non-ACHD. In this relatively large PH cohort, ACHD patients had considerably higher PAP and lower pulmonary blood flow. With CPX, ACHD patients had a lower peak VO 2 and higher VE/VCO 2 slope, two strong predictors of outcomes in HF and PH. 9, 11, 12, 14 Even after the ACHD and non-ACHD patients were matched by 44 pairs for gender and peak VO 2 , the ACHD patients had considerably higher levels of PAP and the VE/VCO 2 slope, which would suggest a worse prognosis at any given level of peak VO 2 . This is a very interesting paper, although we wish additional information was available on patient demographics, hemoglobin/hematocrit, and other potential important variables. As the authors mentioned, ACHD is a heterogenous group of patients, and although this ACHD group was relatively small (N ¼ 57), it represented the typical heterogeneity.
Also, as the authors mentioned, ACHD patients have undergone several adaptive mechanisms over time due to their prolonged and varying exposure to reduced oxygen delivery, and for this reason they have different time courses for their disease. In our ACHD practices, we often define their functional limitation based on peak VO 2 , which is used to evaluate symptoms and also appropriate timing of the various therapeutic interventions available.
Indeed, there are published data, which provide a nomogram for peak VO 2 (as percentage predicted) for specific ACHD abnormalities. 15, 16 Interestingly, the mean peak VO 2 in the current study (approximately 13 AE 4 mL mlO 2 Á kg À1 Á min À1 ) is similar to complex ACHD and Eisenmenger syndrome. Certainly, the patients with ACHD in the current study had a more complex form of ACHD with perhaps late repairs of atrial septal defect, patent ductus arteriosus, and ventricular septal defect repairs.
The patients with ACHD also have numerous confounding parameters, which can affect their VE/VCO 2 slope, including restrictive lung disease, anemia, cachexia, and other disorders. Certainly, the VE/VCO 2 slope predicts mortality in HF and non-cyanotic ACHD patients. In fact, a slope greater than 38 was associated with a 2-year survival of only 86%, while a slope less than 38 was associated with 99% 2-year survival. 17 Based on the 2012 data from Kempny et al., 15 VE/VCO 2 slope data are much worse in the current paper, with only the Fontan patients (N ¼ 590) and Eisenmenger patients (N ¼ 43) typically being greater than 40. One explanation for this is that the patients in the current study had considerably lower peak VO 2 and worse PH. In the present study, CPX was performed with bicycle ergometry, which may lead to better responses with both the VE/VCO 2 slope and the partial pressure of end-tidal carbon dioxide (P ET CO 2 ) compared to responses during treadmill exercise. 11, 12, 18 Therefore, values obtained from different CPX modes of testing should not be considered interchangeable, and serial CPX measures should be conducted using the same exercise modality. Also, in this study, the VE/VCO 2 slope is significantly above normal in both the ACHD and non-ACHD cohorts, but was significantly worse in those with ACHD, even at a similar exercise capacity or peak VO 2 . Although it is unclear what the long-term prognostic implications are of a much higher VE/VCO 2 slope, as this may reflect PH severity and is an independent prognostic marker, often outperforming peak VO 2 in PH and HF. 11, 12, 14 This issue should be assessed by further research. In addition, various therapeutic modalities, including exercise training, in patients with ACHD with and without PH to improve endothelial function and reduce arterial stiffness 11, 12, 19 also require considerable further study.
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